Literature DB >> 8632575

Prediction of capsular perforation and seminal vesicle invasion in prostate cancer.

D G Bostwick1, J Qian, E Bergstralh, P Dundore, J Dugan, R P Myers, J E Oesterling.   

Abstract

PURPOSE: Capsular perforation and seminal vesicle invasion are unfavorable prognostic factors in prostate cancer. Accurate preoperative prediction of these factors would be clinically useful for planning treatment, especially in patients being considered for radiation therapy, nerve sparing radical prostatectomy and watchful waiting. However, current methods are imprecise at predicting the presence and extent of these factors. We determined which combination of commonly available preoperative variables provides the best prediction of capsular perforation and seminal vesicle invasion of patients with clinically localized prostate cancer.
MATERIALS AND METHODS: We reviewed the preoperative medical records and biopsy findings from 314 patients with clinical stages T1cN0M0 to T2cN0M0 cancer who underwent radical retropubic prostatectomy and bilateral pelvic lymphadenectomy between September 1991 and June 1993. Radical prostatectomy specimens were embedded and evaluated by whole mount sections.
RESULTS: Capsular perforation was observed in 104 patients (33.1%) and seminal vesicle invasion was noted in 46(14.6%). Preoperative variables predictive of capsular perforation and seminal vesicle invasion on univariate analysis were serum prostate specific antigen (PSA) concentration, clinical, stage, Gleason primary and secondary patterns, Gleason score, nuclear grade, perineural invasion and percent cancer in the biopsy specimens. On multivariate analysis, independent prognostic factors for capsular perforation and seminal vesicle invasion were PSA, Gleason score and percent cancer in the biopsy specimens.
CONCLUSIONS: The combination of serum PSA concentration, Gleason score and percent cancer in the biopsy specimens provides the best prediction of capsular perforation and seminal vesicle invasion. Models based on this combination of factors may be clinically use to stratify patients for nonoperative treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8632575

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  Biopsy diagnosis of prostatic cancer--current areas of concern.

Authors:  M R Feneley; M C Parkinson
Journal:  J Clin Pathol       Date:  1997-04       Impact factor: 3.411

2.  Seminal vesicle invasion in prostate cancer: evaluation by using multiparametric endorectal MR imaging.

Authors:  Fatma Nur Soylu; Yahui Peng; Yulei Jiang; Shiyang Wang; Christine Schmid-Tannwald; Ila Sethi; Scott Eggener; Tatjana Antic; Aytekin Oto
Journal:  Radiology       Date:  2013-02-25       Impact factor: 11.105

Review 3.  Stage T1c prostate cancer: defining the appropriate staging evaluation and the role for pelvic lymphadenectomy.

Authors:  M C Beduschi; R Beduschi; J E Oesterling
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

4.  Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort.

Authors:  Ramzi Rajab; Gabrielle Fisher; Michael W Kattan; Christopher S Foster; Tim Oliver; Henrik Møller; Victor Reuter; Peter Scardino; Jack Cuzick; Daniel M Berney
Journal:  Virchows Arch       Date:  2010-09-09       Impact factor: 4.064

5.  Explainable artificial intelligence to predict the risk of side-specific extraprostatic extension in pre-prostatectomy patients.

Authors:  Jethro C C Kwong; Adree Khondker; Christopher Tran; Emily Evans; Adrian I Cozma; Ashkan Javidan; Amna Ali; Munir Jamal; Thomas Short; Frank Papanikolaou; John R Srigley; Benjamin Fine; Andrew Feifer
Journal:  Can Urol Assoc J       Date:  2022-06       Impact factor: 2.052

Review 6.  Critical review of prostate cancer predictive tools.

Authors:  Shahrokh F Shariat; Michael W Kattan; Andrew J Vickers; Pierre I Karakiewicz; Peter T Scardino
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

7.  Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81.

Authors:  Sook Shin; Tae-Dong Kim; Fang Jin; Jan M van Deursen; Scott M Dehm; Donald J Tindall; Joseph P Grande; Jan-Marie Munz; George Vasmatzis; Ralf Janknecht
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

8.  The free-to-total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer.

Authors:  Erim Erdem; Necmettin Atsü; Cem Akbal; Cenk Y Bilen; Ali Ergen; Haluk Ozen
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

9.  Variation in reporting of cancer extent and benign histology in prostate biopsies among European pathologists.

Authors:  D M Berney; F Algaba; P Camparo; E Compérat; D Griffiths; G Kristiansen; A Lopez-Beltran; R Montironi; M Varma; L Egevad
Journal:  Virchows Arch       Date:  2014-03-04       Impact factor: 4.064

10.  Expression of stromal elements of prostatic adenocarcinoma in different gleason scores.

Authors:  Clarice Fraga Esteves Maciel Osorio; Waldemar Silva Costa; Carla Braga Mano Gallo; Francisco José Barcellos Sampaio
Journal:  Acta Cir Bras       Date:  2019-12-13       Impact factor: 1.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.